Cryptococcosis: Update and emergence of Cryptococcus gattii

Veterinary Clinical Pathology

Volumn 40, Issue 1, 2011, Pages 4-17

  Lester, Sally J ^a   Malik, Richard ^b   Bartlett, Karen H ^c   Duncan, Colleen G ^d  

^a Pilchuck Veterinary Hospital   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Colonization; Diagnosis; Infection; Therapy; Yeast

Indexed keywords

ANTIFUNGAL AGENT; FUNGUS ANTIGEN;

ANIMAL; ANIMAL DISEASE; BLOOD; CAT; CAT DISEASE; COMMUNICABLE DISEASE; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DOG; DOG DISEASE; MICROBIOLOGY; NORTH AMERICA; PATHOGENICITY; PHYSIOLOGY; PROGNOSIS; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; CAT DISEASES; CATS; COMMUNICABLE DISEASES, EMERGING; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DOG DISEASES; DOGS; NORTH AMERICA; PROGNOSIS;

AVES; CRYPTOCOCCUS GATTII; MAMMALIA;

EID: 79951765219     PISSN: 02756382     EISSN: 1939165X     Source Type: Journal    
DOI: 10.1111/j.1939-165X.2010.00281.x     Document Type: Review

References (101)

1. Holzworth J. Cryptococcosis in a cat. Cornell Vet. 1952;42:12-15.
2. Blaschke-Hellmessen R. Cryptococcus species-etiological agents of zoonoses or sapronosis. Mycoses. 2000;43 (Suppl 1):48-60.
3. Sykes JE, Malik R. Cryptococcosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Philadelphia, PA: WB Saunders; 2011: in press.
4. Bovers M, Hagen F, Boekhout T. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Micol. 2008;25:S4-S12.
5. Findley K, Rodriguez-Carres M, Metin B, et al. Phylogeny and phenotypic characteristics of pathogenic Cryptococcus species and closely related saprobic taxa in the tremellales. Eukaryot Cell. 2009;8:353-361.
6. Bovers M, Hagen F, Kuramae EE, et al. AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis. 2008;14:1105-1108.
7. Franzot SP, Fries BC, Cleare W, et al. Genetic relationship between Cryptocoocus neoformans var. neoformans strains of serotypes A and D. J Clin Microbiol. 1998;36:2200-2204.
8. Fagnello J, Dutra V, Schrank A, Meyer W, Schrank IS, Vainstein MH. Identification of genomic differences between Cryptococcus neoformans and Cryptococcus gattii by representational difference analysis (RDA). Med Mycol. 2009;47:584-591.
9. Meyer W, Marszewska K, Amirmostofian M, et al. Molecular typing of global isolates of C. neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiologic study. Electrophoresis. 1999;20:1790-1799.
10. Bovers M, Hagen F, Kuramae EE, Boekhout T. Six monophyletic lineages identified within Cryptococcus neoformans and Cryptococcus gattii by multi-locus sequence typing. Fungal Genet Biol. 2008;45:400-421.
11. Sorrell TC, Chen SCA, Ruma P, et al. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J Clin Microbiol. 1996;34:1253-1260.
12. Kidd SE, Guo H, Bartlett KH, Xu J, Kronstad JW. Comparative gene genealogies indicate that two clonal lineages of Cryptococcus gattii in British Columbia resemble strains from other geographical areas. Eukaryot Cell. 2005;4:1629-1638.
13. Xue C, Tada Y, Dong X, Heitman J. The human fungal pathogen Cryptococcus can complete its sexual cycle during a pathogenic association with plants. Cell Host Microbe. 2007;1:263-273.
14. Lin X, Hull CM, Heltman J. Sexual reproduction between partners of the same mating type in Cryptococcus neoformans. Nature. 2005;434:1017-1021.
15. Fraser JA, Subaran RL, Nichols CB, Heitman J. Recapitulation of the sexual cycle of the primary fungal pathogen Cryptococcus neoformans var. gattii: implications for an outbreak on Vancouver Island, Canada. Eukaryot Cell. 2003;2:1036-1045.
16. Hull CM, Davidson RC, Heitman J. Cell identity and sexual development in Cryptococcus neoformans are controlled by the mating-type-specific homeodomain protein Sxi1α. Genes Dev. 2002;16:3046-3060.
17. Saul N, Krockenberger M, Carter D. Evidence of recombination in mixed-mating-type and α-only populations of Cryptococcus gattii sourced from single Eucalyptus tree hollows. Eukaryot Cell. 2008;7:727-734.
18. Halliday CL, Bui T, Krockenberger M, Malik R, Ellis DH, Carter DA. Presence of the α and a mating types in environmental and clinical collections of Cryptococcus neoformans var. gattii strains from Australia. J Clin Microbiol. 1999;37:2920-2926.
19. Bui T, Lin X, Malik R, Heitman J, Carter DA. Isolates of Cryptococcus neoformans from infected animals reveal genetic exchange in unisexual mating type populations. Eukaryot cell. 2008;7:1771-1780.
20. Labrecque O, Sylvestre D, Messier S. Systemic Cryptococcus albidus infection in a Doberman Pinscher. J Vet Diagn Invest. 2005;17:598-600.
21. Kano R, Kitagawa M, Oota S, et al. First case of feline systemic Cryptococcus albidus infection. Med Mycol. 2008;46:75-77.
22. Bernardo FM, Martins HM, Martins ML. A survey of mycotic otitis externa of dogs in Lisbon. Rev Iberoam Micol. 1998;15:163-165.
23. Kano R, Hosaka S, Hasegawa A. First isolation of Cryptococcus magnus from a cat. Mycopathologia. 2004;157:263-264.
24. Buchanan KL, Murphy JW. What makes Cryptococcus neoformans a pathogen? Emerg Inf Dis. 1998;4:71-83.
25. Kraus PS, Nicols CB, Heltman J. Calcium and calcineurin-independent roles for calmodulin in Cryptococcus neoformans morphogenesis and high-temperature growth. Eukaryot Cell. 2005;4:1079-1087.
26. Chung S, Mondon P, Chang YC, Kwon-Chung KJ. Cryptococcus neoformans with a mutation in the tetratricopeptide repeat-containing gene CCN1, causes subcutaneous lesions but fails to cause systemic infection. Infect Immun. 2003;71:1988-1994.
27. Ren P, Springer DJ, Behr M, Samsonoff WA, Chaturvedi S, Chaturvedi V. Transcription factor STE12α has distinct roles in morphogenesis, virulence and ecological fitness of the primary pathogenic yeast Cryptococcus gattii. Eukaryot Cell. 2006;5:1065-1080.
28. Narasipura SD, Chaturvedi V, Chaturvedi S. Characterization of Cryptococcus neoformans variety gattii SOD2 reveals distinct roles of the two superoxide dismutases in fungal biology and virulence. Mol Microbiol. 2005;55:1782-1800.
29. Giles SS, Stajich JE, Nichols C, et al. The Cryptococcus neoformans catalase gene family and its role in antioxidant defense. Eukaryot Cell. 2006;5:1447-1459.
30. Wozniak KL, Levitz SM. Isolation and purification of antigenic components of Cryptococcus. Methods Mol Biol. 2009;470:71-83.
31. Liu OW, Kelly MJS, Chow ED, Madhani HD. Parallel β-Helix proteins required for accurate capsule polysaccharide synthesis and virulence in the yeast Cryptococcus neoformans. Eukaryot cell. 2007;6:630-640.
32. Schop J. Protective immunity against Cryptococcus neoformans. Mcgill J Med. 2007;10:35-43.
33. Jain N, Cook E, Xess I, Hasan F, Fries D, Fries BC. Isolation and characterization of senescent Cryptococcus neoformans and implications for phenotypic switching and pathogenesis in chronic cryptococcosis. Eukaryot Cell. 2009;8:858-866.
34. Ngamskulrungroj P, Himmelreich U, Breger JA, et al. The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii. Infect Immun. 2009;77:4584-4596.
35. Ngamskulrungroj P, Serena C, Gigado F, Malik R, Meyer W. Global VGIIa isolates are of comparable virulence to the major fatal Cryptococcus gattii Vancouver Island outbreak genotype. Clin Microbiol Infect. Epub ahead of print, doi: DOI: 10.1111/j.1469-0691.2010.03222.x.
36. Ngamskulrungroj P, Sorrell TC, Chindamporn A, Chaiprasert A, Poonwan N, Meyer W. Association between fertility and molecular sub-type of global isolates of Cryptococcus gattii molecular type VGII. Med Mycol. 2008;46:665-673.
37. Springer DJ, Chaturvedi V. Projecting global occurrence of Cryptococcus gattii. Emerg Infect Dis. 2010;16:114-120.
38. Byrnes EJ, Wenjun Li, Lewit Y, et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathogens. 2010;6:e1000850.
39. Hansong M, Hagen F, Stekel DJ, et al. The fatal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. PNAS. 2009;106:12980-12985.
40. Idnurm A, Walton FJ, Floyd A, Reedy JL, Heitman J. Identification of ENA1 as a virulence gene of the human pathogenic fungus Cryptococcus neoformans through signature-tagged insertional mutagenesis. Eukaryot Cell. 2009;8:315-326.
41. Wright L, Bubb W, Davidson J, et al. Metabolites released by Cryptococcus neoformans var. neoformans and var. gattii differentially affect human neutrophil function. Microbes Infect. 2002;4:1427-1438.
42. Loftus BJ, Fung E, Roncaglia P, et al. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science. 2005;307:1321-1324.
43. Barreto de Oliveira MT, Boekhout T, Theelen B, et al. Cryptococcus neoformans show remarkable genotypic diversity in Brazil. J Clin Microbiol. 2004;42:1356-1359.
44. Steenbergen JN, Casadevall A. Prevalence of Cryptococcus neoformans var. neoformans (serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City. J Clin Microbiol. 2000;38:1974-1976.
45. Sorrell TC, Brownlee AG, Ruma P, Malik R, Pfeiffer TJ, Ellis DH. Natural environmental sources of Cryptococcus neoformans var. gattii. J Clin Microbiol. 1996;34:1261-1263.
46. Campbell LT, Currie BJ, Krockenberger M, et al. Clonality and recombination in genetically differentiated subgroups of Cryptococcus gattii. Eukaryot Cell. 2005;4:1403-1409.
47. Frases S, Ferrer C, Sanchez M, Colom-Valiente MF. Molecular epidemiology of isolates of Cryptococcus neoformans species complex from Spain. Rev Iberoam Micol. 2009;26:112-117.
48. Ollixures LRC, Martinez KM, Cruz RMB, et al. Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by PCR fingerprinting. Med Mycol. 2009;48:1-9.
49. Chaturvedi S, Dyavaiah M, Larsen RA, Chaturvedi V. Cryptococcus gattii in AIDS patients in southern California. Emerg Infect Dis. 2005;11:1686-1692.
50. Galanis E, MacDougall L. Epidemiology of Cryptococcus gattii, British Columbia, Canada 1999-2007. Emerg Infect Dis. 2010;16:251-257.
51. Stephen C, Lester S, Black W, Fyfe M, Raverty S. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J. 2002;43:792-794.
52. Byrnes EJ, Bildfell RJ, Dearing PL, Valentine BA, Heitman J. Cryptococcus gattii with biomorphic colony types in a dog in western Oregon: additional evidence for expansion of the Vancouver Island outbreak. J Vet Diagn Invest. 2009;21:133-136.
53. Kidd SE, Bach PJ, Hingston AO, et al. Cryptococcus gattii dispersal mechanisms, British Columbia, Canada. Emerg Infect Dis. 2007;13:151-157.
54. MacDougall L, Kidd SE, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the pacific northwest, USA. Emerg Infect Dis. 2007;13:42-50.
55. Byrnes EJ, Wenjun Li, Lewit Y, et al. First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One. 2009;4:e5851-e5870.
56. Sykes JE. Epidemiology of Cryptococcus infections. Proceedings of the American College of Veterinary Internal Medicine Forum, Anaheim, CA, June 9-12, 2010; 602-603.
57. Malik R, Wigney DI, Muir DB, Love DN. Asymptomatic carriage of Cryptococcus neoformans in the nasal cavity of dogs and cats. J Med Vet Mycol. 1997;35:27-31.
58. Krockenberger MB, Canfield PJ, Barnes J, et al. Cryptococcus neoformans var. gattii in the koala (Phascolarctos cinereus): serological evidence for subclinical cryptococcosis. Med Mycol. 2002;40:273-282.
59. Duncan C, Stephen C, Lester S, Bartlett KH. Sub-clinical infection and asymptomatic carriage of Cryptococcus gattii in dogs and cats during an outbreak of cryptococcosis. Med Mycol. 2005;43:511-516.
60. Duncan C, Stephen C, Lester S, Bartlett KH. Follow-up study of dogs and cats with asymptomatic Cryptococcus gattii infection or nasal colonization. Med Mycol. 2005;43:663-666.
61. Velagapudi R, Hsueh Y, Geunes-Boyer S, Wright JR, Heitman J. Spores as infectious propagules of Cryptococcus neoformans. Infect Immun. 2009;77:4345-4355.
62. Giles SS, Dagenais TR, Botts MR, Keller NP, Hull CM. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect Immun. 2009;77:3491-3500.
63. McGill S, Malik R, Saul N, et al. Cryptococcosis in domestic animals in western Australia: a retrospective study from 1995-2006. Med Mycol. 2009;47:625-639.
64. Lester SL, Kowalewich NJ, Bartlett KH, Krockenberger MB, Fairfax TM, Malik R. Clinicopathologic features of an unusual outbreak of cryptococcosis in dogs, cats, ferrets and a bird: 38 cases (January to July 2003). J Am Vet Med Assoc. 2004;225:1716-1722.
65. MacDougall L, Fyfe M. Emergence of Cryptococcus gattii in a novel environment provides clues to its incubation period. J Clin Microbiol. 2006;44:1851-1852.
66. Kluger EK, Karoglu HK, Krockenberger MB, Torre D, Meyer W, Malik R. Recrudescent cryptococcosis, caused by Cryptococcus gattii (Molecular type VGII) over a 13 year period in a Birman cat. Med Mycol. 2006;44:561-566.
67. Duncan C, Schwantje H, Stephen C, Campbell J, Bartlett K. Cryptococcus gattii in wildlife of Vancouver Island, British Columbia, Canada. J Wildlife Dis. 2006;42:175-178.
68. O'Brien CR, Krockenberger MB, Wigney DI, Martin P, Malik R. Retrospective study of feline and canine cryptococcosis in Australia from 1981 to 2001: 195 cases. Med Mycol. 2004;42:449-460.
69. Malik R, Wigney DI, Muir DB, Gregory DJ, Love DN. Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment with fluconazole. J Med Vet Mycol. 1992;30:133-144.
70. Chapman TL, Kirk SE. An isolated cryptococcal urinary tract infection in a cat. J Am Anim Hosp Assoc. 2008;44:262-265.
71. Belluco S, Thibaud JL, Guillot J, et al. Spinal cryptococcoma in an immunocompetent cat. J Comp Path. 2008;139:246-251.
72. Tisdall PL, Martin P, Malik R. Cryptic disease in a cat with painful and swollen hocks: an exercise in diagnostic reasoning and clinical decision making. J Fel Med Surg. 2007;9:418-423.
73. Walker C, Malik R, Canfiled PJ. Analysis of leukocytes and lymphocyte subsets in cats with naturally-occurring cryptococcosis but differing feline immunodeficiency virus status. Aust Vet J. 1995;72:93-97.
74. Duncan CG, Stephen C, Campbell J. Evaluation of risk factors for Cryptococcus gattii infection in dogs and cats. J Am Vet Med Assoc. 2006;228 (3):377-382.
75. Duncan C, Stephen C, Campbell J. Clinical characteristics and predictors of mortality for Cryptococcus gattii infection in dogs and cats in southwestern British Columbia. Can Vet J. 2006;47:993-998.
76. Malik R, Dill-Macky E, Martin P, Wigney DI, Muir DB, Love DN. Cryptococcosis in dogs: a retrospective study of 20 consecutive cases. J Med Vet Mycol. 1995;33:291-297.
77. Bowles DB, Fry DR. Nasal cryptococcosis in two dogs in New Zealand. N Z Vet J. 2009;57:53-57.
78. Newman SJ, Langston CE, Scase TJ. Cryptococcal pyelonephritis in a dog. J Am Vet Med Assoc. 2003;222:180-183.
79. Malik R, Krockenberger MB, Cross G, et al. Avian cryptococcosis. Med Mycol. 2003;41:115-124.
80. Cruz CV, Sommardahl CS, Chapman EA, Fry MM, Schmacher J. Successful treatment of a sinonasal cryptococcal granuloma in a horse. J Am Vet Med Assoc. 2009;234:509-513.
81. Hart KA, Flaminio MJ, Leroy BE, Williams CO, Dietrich UM, Barton MH. Successful resolution of cryptococcal meningitis and optic neuritis in an adult horse with oral fluconazole. J Vet Intern Med. 2007;22:1436-1440.
82. Lenard ZM, Lester NV, O'Hara AJ, Hopper BJ, Lester GD. Disseminated cryptococcosis including osteomyelitis in a horse. Aust Vet J. 2007;85:51-55.
83. Begg LM, Hughes KJ, Kessell A, Krockenberger MB, Wigney DI, Malik R. Successful treatment of cryptococcal pneumonia in a pony mare. Aust Vet J. 2004;82:686-692.
84. Stewart AJ, Salazar T, Waldridge BM, et al. Multinodal treatment of recurrent sinonasal cryptococcal granulomas in a horse. J Am Vet Med Assoc. 2009;235:723-730.
85. Malik R, Alderton B, Finlaison D, et al. Cryptococcosis in ferrets: a diverse spectrum of clinical disease. Aust Vet J. 2002;80:749-755.
86. Hanley CS, MacWilliams P, Glies S, Pare J. Successful treatment of Cryptococcus neoformans var. grubii in a domestic ferret. Can Vet J. 2006;47:1015-1017.
87. Medleau L, Greene CE, Rakich PM. Evaluation of ketoconazole and itraconazole for treatment of disseminated cryptococcosis in cats. Am J Vet Res. 1990;51:1454-1458.
88. Klein KR, Hall L, Demi SM, Rysavy JM, Wohlfiel SL, Wengenack NL. Identification of Cryptococcus gattii by use of l-canavanine glycine bromothymol blue medium and DNA sequencing. J Clin Microbiol. 2009;47:3669-3672.
89. Krockenberger MB, Canfiled PJ, Kozel TR, et al. An immunohistochemical method that differentiates Cryptococcus neoformans varieties and serotypes in formalin-fixed paraffin embedded tissues. Med Mycol. 2001;39:523-533.
90. Malik R, McPetrie R, Wigney DI, Craig AJ, Love DN. A latex cryptococcal antigen agglutination test for diagnosis and monitoring of therapy for cryptococcosis. Aust Vet J. 1996;74:358-364.
91. Jacobs GJ, Medleau L, Clavert C, Brown J. Cryptococcal infection in cats: factors influencing treatment outcome and results of sequential serum antigen titers in 35 cats. J Vet Intern Med. 1997;11:1-4.
92. Medleau L, Marks A, Brown J, Borges WL. Clinical evaluation of a cryptococcal antigen latex agglutination test for diagnosis of cryptococcosis in cats. J Am Vet Med Assoc. 1990;196:1470-1473.
93. Flatland B, Greene RT, Lappin MR. Clinical and serologic evaluation of cats with cryptococcosis. J Am Vet Med Assoc. 1996;209:1110-1113.
94. O'Brien CR, Krockenberger MB, Martin P, Wigney DI, Malik R. Long-term outcome of therapy for 59 cats and 11 dogs with cryptococcosis. Aust Vet J. 2006;84:384-392.
95. Malik R, Craig AJ, Wigney DI, Martin P, Love DN. Combination chemotherapy of canine and feline cryptococcosis using subcutaneously administered amphotericin B. Aust Vet J. 1996;73:124-128.
96. Pfaller MA, Messer SA, Bolmstrom A, Odds FC, Rex JH. Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 1996;34:1691-1693.
97. Espinel-Ingroff A, Pfaller MA, Erwin ME, Jones RN. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using casiton agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol. 1996;34:849-852.
98. Pfaller MA, Messer SA, Karlsson A, Bolmstrom A. Evaluation of the E-test method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol. 1998;36:2586-2589.
99. Bernal-Martinez L, Gomez-Lopez A, Castelli MV, et al. Susceptibility profile of clinical isolates of non-cryptococcus neoformans/non-cryptococcus gattii Cryptococcus species and literature review. Med Mycol. 2009;23:1-7.
100. Iqbal N, DeBess EE, Wohrle R, et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the pacific northwest of the United States. J Clin Microbiol. 2010;48:539-544.
101. Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T, Baro-Tomas T. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and Voriconazole. Med Mycol. 2005;43:505-510.